The stock’s recovery is getting an extra boost from a massive broader market rally. U.S. equities surged across the board after the United States and Iran came to a historic peace agreement, effectively ending their conflict and reopening the critical Strait of Hormuz shipping lane.Here’s what investors need to know.
Hims & Hers Health shares are climbing with conviction. What’s fueling HIMS momentum?
Last week, the company named Anant Vinjamoori as chief medical officer, leaning into clinical credibility and a medical leadership bench with more than 100 years of combined experience across weight loss, sexual health, hormone health, mental health, dermatology, and primary care. The company’s message is a push beyond episodic treatment toward longer-duration customer relationships, where retention and expansion matter more than one-off demand.HIMS Stock: Key Technical Levels To WatchTechnically, HIMS is back in "rebuild" mode: it's trading above its 20-day SMA ($25.89), 50-day SMA ($25.63), and 100-day SMA ($23.49), but it's still trading below its 200-day SMA ($33.57), which keeps the longer-term trend pressure in view. That split often shows up when a stock is repairing damage but hasn't fully flipped the long-term trend.Momentum is best framed by RSI, which is at 52.06—neutral, and consistent with a stock that's trying to base rather than sprinting into an overbought breakout. In plain English, RSI helps gauge whether a move is getting stretched; around the low-50s suggests neither buyers nor sellers have a clear momentum edge right now.The bigger overhang is structural: the death cross from December 2025 (50-day SMA below the 200-day SMA) is still in place, which is why bulls typically want to see follow-through that starts reclaiming longer-term averages. The recent swing low in March and swing high in April also reinforce that the stock has been trading more like a range-and-repair setup than a clean trend.
